Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BET inhibition
Biotech
Novartis only wanted pelabresib, but MorphoSys had other ideas
A peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away with one specific asset.
James Waldron
Apr 12, 2024 8:53am
MorphoSys fails secondary in blood cancer trial, sinking stock
Nov 21, 2023 5:52am
Vyne swings behind BET, seeks partner for failed eczema drug
Mar 10, 2023 9:30am
Turning Gilead's Zydelig against triple-negative breast cancer
Mar 12, 2020 8:00am
Aptose signs $125M-plus BET inhibitor deal with Ohm
Mar 7, 2018 9:32am
Moving PARP inhibitors beyond BRCA cancers
Jul 26, 2017 3:14pm